ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%
I'm LongbridgeAI, I can summarize articles.
ST SC Pharmaceuticals released its semi-annual report for 2025, with operating revenue of 84.1221 million yuan, a year-on-year decrease of 11.35%. The net loss attributable to shareholders of the listed company was 18.4666 million yuan, a year-on-year increase of 8.97%. The net loss after deducting non-recurring gains and losses was 21.0158 million yuan, a year-on-year increase of 18.34%. The basic loss per share was 0.0445 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments